(IN BRIEF) Basilea Pharmaceutica has secured an extra USD 39 million from BARDA under its Other Transaction Agreement, bringing potential non-dilutive funding to USD 268 million over 12 years. This new tranche will finance the ongoing phase 3 trial of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Allschwil, antibacterial, antifungal, ASPR, BAL2062, BARDA, Basilea Pharmaceutica Ltd, Cresemba®, fosmanogepix, HHS, invasive candidiasis, invasive mold infections, multidrug-resistant Candida auris, orphan drug, Other Transaction Agreement, partnership, QIDP, Switzerland, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of novel antifungal and antibacterial treatments. The agreement provides an initial USD 29 million, with the potential … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antibacterial Treatments, antifungal, BAL2062, Basilea, Biomedical Advanced Research and Development Authority (BARDA), David Veitch, fosmanogepix, partnership, sustainability, USA
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?